Although GLP-1 agonists and DPP4 and SGLT2 inhibitors are in widespread use in T2DM subjects, there is little clinical data presented here on the beneficial effects of these drugs on cognition or adverse events in either T2DM or MCI/AD subjects. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.